Supplements of vitamins B9 and B12 affect hepatic and mammary gland gene expression profiles in lactating dairy cows

Bazoumana Ouattara1*, Nathalie Bissonnette1, Melissa Duplessis1,2 and Christiane L. Girard1

Abstract

Background: A combined supplement of vitamins B9 and B12 was reported to increase milk and milk component yields of dairy cows without effect on feed intake. The present study was undertaken to verify whether this supplementation positively modifies the pathways involved in milk and milk component synthesis. Thus, by studying the transcriptome activity in these tissues, the effect of supplements of both vitamins on the metabolism of both liver and mammary gland, was investigated. For this study, 24 multiparous Holstein dairy cows were assigned to 6 blocks of 4 animals each according to previous 305-day milk production. Within each block, cows were randomly assigned to weekly intramuscular injections of 5 mL of either saline 0.9 % NaCl, 320 mg of vitamin B9, 10 mg of vitamin B12 or a combination of both vitamins (B9 + B12). The experimental period began 3 weeks before the expected calving date and lasted 9 weeks of lactation. Liver and mammary biopsies were performed on lactating dairy cows 64 ± 3 days after calving. Samples from both tissues were analyzed by microarray and qPCR to identify genes differentially expressed in hepatic and mammary tissues.

Results: Microarray analysis identified 47 genes in hepatic tissue and 16 genes in the mammary gland whose expression was modified by the vitamin supplements. Gene ontology (GO) categorizes genes in non-overlapping domains of molecular biology. Panther is one of the online GO resources used for gene function classification. It classifies the 63 genes according to Molecular Function, Biological Process and Protein Class. Most of the biological processes modulated by the vitamin supplements were associated to developmental process, protein metabolic process, transport and response to inflammation. In the liver, most of the genes modulated by the vitamin treatments involved protein metabolic process while developmental process appeared to be more affected by the treatments in mammary gland. Out of 25 genes analysed by qPCR, 7 were validated.

Conclusion: The results indicate that several metabolic processes were modulated by the supplementation of vitamins in early-lactating dairy cows. In addition, the results suggest that the vitamin supplements promoted liver regeneration and reduced catabolism of lipids in early lactation.

Keywords: Dairy cow, Liver, Mammary gland, Vitamin B9, Vitamin B12, Microarray

Background

Bacteria present in rumen synthesize B vitamins in generally sufficient amounts to meet their host’s requirements [1]. Notwithstanding, high-producing dairy cows could benefit from vitamin B9 and B12 supplements, especially during the critical period around calving and in early lactation [2–4]. Vitamin B9 plays a major role in DNA synthesis and in de novo formation of methyl groups required for the methylation cycle. On the other hand, vitamin B12 is involved in two metabolic pathways: the remethylation cycle and as coenzyme of the methylmalonyl-CoA mutase. The former, closely related to folate metabolism, is required for the regeneration of methionine and tetrahydrofolate, whereas the latter allows the entry of propionate in the Krebs cycle and gluconeogenesis [5].

Results from two studies suggest that supplementary vitamin B9 might improve efficiency of nutrient utilization,
especially for milk protein synthesis [6, 7]. This observation is supported by the observation that in vitro hormonal stimulation of milk protein synthesis by mammary gland explants of dairy cows increased expression of 28 genes; among them, 2 genes related to folate metabolism, FOLR1 and ALDH1L1 [8]. The former is a folate transporter allowing the entry of 5-methyl-tetrahydrofolate into the cells whereas the latter is involved in purine synthesis. As vitamin B9 supplement increases milk protein synthesis, it would be interesting to investigate whether similar transcriptomic process takes place in vivo when vitamin supplements are provided to lactating cows.

A combined supplement of vitamins B9 and B12 given during the peripartum period and in early lactation altered energy partitioning during the first weeks of lactation as compared to control cows [3, 4, 9]. However, the mode of action of this supplement is not fully elucidated. We observed that a combined supplement of vitamins B9 and B12 increases whole-body rate of appearance of glucose which is the sum of glucose from portal absorption, glyco- genolysis, and gluconeogenesis [3]. Propionate originating from rumen fermentation is the major precursor of glucose in cows [10, 11] and contributes up to 60 % of glucose flux rate [12, 13]. For ruminants, the glucose, essential for synthesis of milk lactose, is mostly provided by liver (up to 90 %) through gluconeogenesis [14].

It has been shown that at the onset of lactation, the liver as well as the mammary gland undergo numerous adaptations to support milk synthesis [15]. In early lactation, feed intake is not sufficient to meet the nutrient demand for milk production, leading to a negative energy balance [15]. Furthermore, the liver undergoes extensive physiological and biochemical changes mediated by significant alterations in hepatic gene expression in an attempt to re-establish metabolic homeostasis and to counteract the adverse effects of negative energy balance [16]. In addition, during this period, the mammary gland is actively remodeling. In fact, by investigating the transcriptional response of the mammary gland during early lactation, Connor et al. [17] observed changes in mammary expression of genes involved in cell proliferation, cellular remodeling, and nutrient transport.

Therefore, the aim of the present project was to profile the genes for which expression undergoes major changes in hepatic and mammary tissues of lactating dairy cows according to vitamins B9 and B12 supply.

Results
At week 9 of lactation, there was no treatment effect ($P \geq 0.1$) on dry matter intake, milk production, milk total solid yields as well as milk component contents. Dry matter intake, milk production, milk total solid yields, milk fat, protein and lactose contents averaged 18.8 (SE 1.9) kg/d, 34.7 (SE 2.9) kg/d, 3.92 (SE 0.33) kg/d, 36.0 (SE 2.0) g/kg, 30.2 (SE 1.4) g/kg, and 46.9 (SE 6.0) g/kg, respectively. During the seven weeks following calving, body condition score losses tended to be reduced (interaction vitamin $\times$ time, $P = 0.10$) in cows receiving the vitamin B9 supplements, alone or combined with vitamin B12. Plasma concentrations of non-esterified fatty acids and $\beta$-hydroxybutyrate were also lower ($P \leq 0.06$), averaging 175 and 243 $\mu$M (SEM 17) and 0.70 and 0.77 mM (SEM 0.03) for cows receiving or not receiving supplementary vitamin B9, respectively.

The microarray analysis revealed that, as compared to control cows receiving no vitamin supplement, the vitamin treatments significantly changed (FDR $\leq 0.05$) the expression of some genes by more than 2-fold in hepatic and mammary tissues (Fig. 1a and b, respectively). The expression of 47 genes in hepatic tissue was modified by at least one of the vitamin treatment compared to control cows (Fig. 1a). From this panel of 47 genes, 41 could be assigned to a biological process using the Panther classification system (Tables 1 and 2). Out of these 47 genes, expression of 14 genes was analyzed by qPCR (Fig. 2). Although nine false positive genes were observed, five genes were confirmed to be differentially expressed in the group of cows supplemented with vitamins.

The expression of two genes was significantly modified in liver by the B9 treatment as illustrated in the Venn diagram (Fig. 1a). One gene that also significantly down-regulated by the B12 treatment was confirmed by qPCR for these cows. This repression of DLK1 in liver was down-regulated by the three vitamin treatments (Fig. 2). The B12 treatment had the greatest impact on the liver with 22 genes (totalizing 39 significant probes; Fig. 1a) whose expression level differed by more than 2-fold compared to control (Table 2).

Among the 22 genes affected by the B12 treatment, four genes were also influenced in cows receiving the B9 + B12 treatment: the metallothioneins 1A (MT1A) and 1E (MT1E), the transmembrane glycoprotein (GPNMB), and an uncharacterized protein (MGC126945) (Table 1). Expression of two of these genes (MT1A and GPNMB) was studied by qPCR (Fig. 2). This analysis confirmed the repression of MT1A in liver of cows receiving B12 and B9 + B12 treatments. Results from the microarray analysis indicated an up-regulation of the expression of GPNMB with both B12 and B9 + B12 treatments. The qPCR analysis showed a numerical but not statistically significant increase with these treatments probably due to the large variation in the expression for this gene among the limited number of animals of this study (Fig. 2). Among the other 17 genes affected by the B12 treatment, the expression of seven genes were studied by qPCR but no effect were confirmed for 6 of them (HERC6, IFI127, ISG15, MEP1B, PPP1R3B and SFRP1). Only the expression of the G0/G1switch 2 gene (G0S2)
was up-regulated in liver of cows receiving the B12 treatment as compared to control (Fig. 2).

In addition to these four genes influenced by B12 treatment, alone and in combination with B9, 24 other genes were affected when both vitamins were administered simultaneously to the cows; four genes were studied by qPCR. Two of them, namely the haptoglobin (HP) and lysyl oxidase-like 4 (LOXL4), were confirmed as being respectively down and up-regulated by the combined treatment. Nevertheless, the expression of LOXL4 was also up-regulated in liver of B9 cows whereas, the expression of HP was down-regulated by all vitamin treatments (Fig. 2). No difference in expression of GSTA5 and SLC22A9 could be detected.

In mammary gland, the B9 treatment modified the expression of nine genes by 2-fold as compared to cows receiving no vitamin supplement. The B12 treatment affected five genes and the expression of five genes was influenced by the B9 + B12 treatment (Fig. 1b). The B9 + B12 shared one gene with the B12 treatment. Based on results from the microarray analysis, three genes whose expression was modified by the B9 treatment (Fig. 1b), cell death-inducing DFFA-like effector a (CIDEA), the androgen binding protein beta-like (LOC785756), and the periostin (POSTN) genes were studied by qPCR in addition to some candidate genes (Fig. 3). Out of the 11 genes analyzed by qPCR, two genes were confirmed; then, the percentage of false positive in the mammary was 82 %. RAB15 and POSTN were significantly up-regulated respectively by the B12 and B9 as compared to control (Fig. 3). Out of the 16 genes affected in the mammary gland by vitamin supplements, 13 were classified using Panther classification system (Table 3).
| Treatment | Gene symbol | Gene name | Treatment effect | Molecular function | Biological process | Protein class |
|-----------|-------------|-----------|------------------|--------------------|--------------------|--------------|
| **B9**    | **DLK1**    | Delta-like 1 homolog (Drosophila) | Down-regulated | receptor activity extracellular matrix structural constituent receptor binding | transcription from RNA polymerase II promoter cell communication ectoderm development nervous system development intracellular protein transport receptor-mediated endocytosis regulation of transcription from RNA polymerase II promoter | membrane-bound signaling molecule receptor extracellular matrix structural protein |
|           | **MYOM1**   | Myomesin-1 | Down-regulated | protein kinase activity structural constituent of cytoskeleton protein binding small GTPase regulator activity guanyl-nucleotide exchange factor activity | protein phosphorylation cell communication cell adhesion muscle contraction mesoderm development muscle organ development regulation of catalytic activity | non-receptor serine/threonine protein kinase non-receptor serine/threonine protein kinase guanyl-nucleotide exchange factor actin family cytoskeletal protein cell adhesion molecule |
| **B12**  | **HERC6**   | HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 | Up-regulated | ligase activity | catabolic process cellular protein modification process proteolysis cellular process | ubiquitin-protein ligase |
|           | **SESN2**   | Sestrin-2  | Up-regulated | oxidoreductase activity peroxidase activity | metabolic process cell cycle | Peroxidase |
|           | **GPNMB**   | glycoprotein (transmembrane) nmb | Up-regulated | receptor binding | cellular process | membrane-bound signaling molecule cell adhesion molecule |
|           | **IFI6**    | Interferon alpha-inducible protein 6 | Up-regulated | Unassigned | Unassigned | Unassigned |
|           | **PPP1R3B** | Protein phosphatase 1 regulatory subunit 3B | Up-regulated | phosphatase activity protein binding phosphatase regulator activity | glycogen metabolic process regulation of catalytic activity | phosphatase modulator |
|           | **ID1**     | ID1 protein | Up-regulated | sequence-specific DNA binding transcription factor activity | transcription from RNA polymerase II promoter regulation of transcription from RNA polymerase II promoter | transcription factor |
|           | **IFI27**   | interferon, alpha-inducible protein 27 | Up-regulated | Unassigned | Unassigned | Unassigned |
|           | **MEP1B**   | meprin A, beta | Up-regulated | oxidoreductase activity serine-type peptidase activity metallopeptidase activity receptor activity lipid transporter activity | immune system process proteolysis synaptic transmission cell-cell adhesion visual perception sensory perception | transporter apolipoprotein membrane-bound signaling molecule receptor metallopeptase |
| Gene     | Description                                      | GO Term                                                                 | Function                                                                                                                                                                                                                                                                                                                                 |
|----------|--------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FUT5     | Fucosyltransferase 5 (alpha (1,3) fucosyltransferase) | transmembrane transporter activity, receptor binding, enzyme regulator activity | ectoderm development, mesoderm development, skeletal system development, angiogenesis, nervous system development, heart development, blood coagulation, lipid transport, intracellular protein transport, endocytosis, vitamin transport, regulation of catalytic activity, serine protease, oxidase, metalloprotease, serine protease, extracellular matrix protein, enzyme modulator, cell adhesion molecule. |
| G0S2     | G0/G1 switch 2                                   | Up-regulated, transferase activity, transferring glycosyl groups         | protein glycosylation, glycosyltransferase                                                                                                                                                                                                                                                                                              |
| CKSR1    | Cyclin-dependent kinase S activator 1            | Up-regulated, kinase activity, protein binding, kinase activator activity | protein phosphorylation, cell cycle, regulation of catalytic activity, kinase activator                                                                                                                                                                                                                                                                                                               |
| ISG15    | Ubiquitin-like protein ISG15                     | Up-regulated, structural constituent of ribosome nucleic acid binding    | proteolysis, ribosomal protein                                                                                                                                                                                                                                                                                                          |
| LOC515676| NFX1-type zinc finger-containing protein 1-like  | Up-regulated, peptidase activity, protein binding, serine-type endopeptidase inhibitor activity | proteolysis, regulation of catalytic activity, serine protease inhibitor.                                                                                                                                                                                                                                                                  |
| SPP1     | Osteopontin                                      | Up-regulated, cytokine activity                                          | immune system process, cellular process, cell adhesion, cellular component, morphogenesis, cellular component organization, cytokine, extracellular matrix protein, defense/immunity protein, cell adhesion molecule.                                                                                                                                                      |
| DLK1     | Delta-like 1 homolog (Drosophila)                | Down-regulated, receptor activity, extracellular matrix structural constituent receptor binding | transcription from RNA polymerase II promoter, cell communication, ectoderm development, nervous system development, intracellular protein transport, receptor-mediated endocytosis, regulation of transcription from RNA polymerase II promoter, membrane-bound signaling molecule receptor, extracellular matrix structural protein. |
| MYOM1    | Myomesin-1                                       | Down-regulated, protein kinase activity structural constituent of cytoskeleton, protein binding, small GTPase regulator activity guanyl-nucleotide exchange factor activity | protein phosphorylation, cell communication, cell adhesion, muscle contraction, mesoderm development, muscle organ development, regulation of catalytic activity, non-receptor serine/threonine protein kinase, non-receptor serine/threonine protein kinase, guanyl-nucleotide exchange factor. |
| Gene          | Description                                      | Annotation Details                                                                 |
|--------------|--------------------------------------------------|-------------------------------------------------------------------------------------|
| MT1E         | Metallothionein                                  | Down-regulated, Unassigned, Unassigned, Unassigned                                  |
| NEFH         | Ortholog, Uncharacterized protein (Fragment)     | Down-regulated, Unassigned, Unassigned, Unassigned                                  |
| SFRP1        | Secreted frizzled-related protein 1              | Down-regulated, receptor activity, protein binding                                   |
| KIAA1324     | KIAA1324 ortholog                                | Down-regulated, Unassigned, Unassigned, Unassigned                                  |
| MGC126945    | Uncharacterized protein                          | Down-regulated, receptor activity, receptor activity                                |
| MT1A         | Metallothionein-1A                               | Down-regulated, Unassigned, Unassigned, Unassigned                                  |
| B9 + B12     | Serum amyloid A protein                          | Down-regulated, lipid transporter activity, transmembrane transporter activity         |
| SAA3         | MHC class I-like family A1                       | Down-regulated, receptor activity                                                   |
| ACMSD        | 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Down-regulated, Unassigned, Unassigned                                               |
| THRSP        | THRSP protein                                    | Down-regulated, Unassigned, Unassigned                                               |
| MGC126945    | Uncharacterized protein                          | Down-regulated, receptor activity, receptor activity                                |

*Table 1: Gene Ontology annotations of the differentially expressed hepatic genes with the Panther Classification System* (Continued)
| Gene        | Description                                                                 | Regulation | GO Terms                                                                 | Additional Terms                      |
|-------------|------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------|----------------------------------------|
| MT1A        | Metallothionein-1A                                                           | Down-regulated | Unassigned                                                                | Unassigned                            |
| C4H7orf57   | chromosome 4 open reading frame, human C7orf57                             | Down-regulated | Unassigned                                                                | Unassigned                            |
| CACNA2D1    | calcium channel, voltage-dependent, alpha 2/delta subunit                   | Down-regulated | cation transmembrane transporter activity                                | cation transport protein targeting    |
| GSTA5       | Glutathione S-transferase                                                    | Down-regulated | Unassigned                                                                | Unassigned                            |
| LOC509034   | feline leukemia virus subgroup C receptor-related protein 2-like           | Down-regulated | transmembrane transporter activity                                        | transport                              |
| NHEDC1      | solute carrier family 9, subfamily B (cation proton antiporter 2), member 1 | Down-regulated | Unassigned                                                                | Unassigned                            |
| SH3YL1      | SH3 domain-containing YSCB4-like protein 1                                  | Down-regulated | structural constituent of cytoskeleton actin binding                     | cellular process non-motor actin binding protein |
| HP          | Haptoglobin                                                                  | Down-regulated | serine-type peptidase activity                                          | gamete generation                     |
|             |                                                                              |             | calcium ion binding                                                       | complement activation                 |
|             |                                                                              |             | calmodulin binding                                                        | protein phospholipid binding          |
|             |                                                                              |             | calcium-dependent phospholipid binding                                   |                                        |
| NGEF        | neuronal guanine nucleotide exchange factor                                 | Down-regulated | Unassigned                                                                | Unassigned                            |
| LGALS3      | Lectin, galactoside-binding, soluble, 3                                      | Up-regulated | receptor binding                                                          | cellular process                      |
| LOC524810   | IgM                                                                          | Up-regulated | Unassigned                                                                | Unassigned                            |
| LOXL4       | Lysyl oxidase homolog 4                                                      | Up-regulated | oxidoreductase activity                                                   | macrophage activation                 |
|             |                                                                              |             | serine-type peptidase activity                                          | apoptotic process                     |
|             |                                                                              |             | receptor activity                                                         | cell communication                    |
|             |                                                                              |             |                                                                          | cell-cell adhesion                    |
|             |                                                                              |             |                                                                          | neurological system process           |
|             |                                                                              |             |                                                                          | cellular defense response             |
|             |                                                                              |             |                                                                          | extracellular transport               |
|             |                                                                              |             |                                                                          | negative regulation of apoptotic process |
|             |                                                                              |             |                                                                          |                                        |
| PYCR1       | Pyrroline-5-carboxylate reductase 1, mitochondrial                           | Up-regulated | oxidoreductase activity                                                   | cellular amino acid biosynthetic process |
| MSMB        | Uncharacterized protein                                                       | Up-regulated | hormone activity                                                          | peptide hormone                       |
| IGLL1       | immunoglobulin lambda-like polypeptide 1                                     | Up-regulated | antigen binding                                                           | B cell mediated immunity response to stimulus |

Table 1 Gene Ontology annotations of the differentially expressed hepatic genes with the Panther Classification System® (Continued)
All genes differentially expressed in liver were classified using the Gene Ontology annotations with the Panther Classification System. Some of these genes were not found by Panther genes list analysing system and some could not be classified. Only three ontology categories are presented: Molecular Function, Biological Process and Protein Class.

*Panther gene list classification system of the genes differentially expressed in hepatic tissue of cows receiving vitamin supplements (vitamin B9 alone: B9, vitamin B12 alone: B12 or both vitamins: B9 + B12) as compared to no vitamins treatment (Control)*
| Biological process                              | Genes                          | Symbol        | Fold Change |
|-----------------------------------------------|--------------------------------|---------------|-------------|
| apoptotic process negative regulation of apoptotic process | LOXL4                          | 1.6           |
| biological adhesion cell adhesion             | MYOM1                          | −2.5          |
|                                               | SPP1                           | 0.9           |
|                                               | MEP1B                          | 1.3           |
|                                               | LOXL4                          | 1.6           |
| biological regulation regulation of biological process | DLK1                           | −2.5          |
|                                               | SFRP1                          | −1.8          |
|                                               | iD1                            | 1.1           |
|                                               | LOXL4                          | 1.6           |
| biological regulation regulation of molecular function | MYOM1                          | −2.5          |
|                                               | CDK5R1                         | 0.8           |
|                                               | PPP1R3B                        | 1.1           |
|                                               | MEP1B                          | 1.3           |
|                                               | LOC515676                      | 1.9           |
| cellular component organization cellular component organization | SPP1                           | 0.9           |
| cellular process cell communication           | DLK1                           | −2.5          |
|                                               | MYOM1                          | −2.5          |
|                                               | SFRP1                          | −1.8          |
|                                               | MEP1B                          | 1.3           |
|                                               | LOXL4                          | 1.6           |
| cellular process cell cycle                   | CDK5R1                         | 0.8           |
|                                               | SESN2                          | 0.9           |
| developmental process anatomical structure morphogenesis | SPP1                           | 0.9           |
| death                                         | LOXL4                          | 1.6           |
| ectoderm development                          | DLK1                           | −2.5          |
|                                               | MEP1B                          | 1.3           |
| mesoderm development                          | MYOM1                          | −2.5          |
|                                               | MEP1B                          | 1.3           |
| system development                            | DLK1                           | −2.5          |
|                                               | MYOM1                          | −2.5          |
|                                               | SFRP1                          | −1.8          |
|                                               | MEP1B                          | 1.3           |
|                                               | IGLL1                          | 2.1           |
| immune system process antigen processing and presentation | LOC100126815                   | −2.4          |
|                                               | MGC126945                      | −1.8          |
| immune response                               | LOC100126815                   | −2.4          |
|                                               | MGC126945                      | −1.8          |
|                                               | HP                             | −1.6          |
|                                               | IGLL1                          | 2.1           |
| macrophage activation                         | LOXL4                          | 1.6           |
| localization transport                         | DLK1                           | −2.5          |
|                                               | LOC509034                      | −1.5          |
|                                               | SAA3                           | −1.1          |
|                                               | CACNA2D1                       | −1.0          |
|                                               | MEP1B                          | 1.3           |
|                                               | LOXL4                          | 1.6           |
| metabolic process catabolic process           | HERC6                          | 1.8           |
| carbohydrate metabolic process                | PPP1R3B                        | 1.1           |
| cellular amino acid metabolic process         | PYCR1                          | 1.5           |
| nucleobase-containing compound metabolic process | DLK1                           | −2.5          |
|                                               | iD1                            | 1.1           |
| protein metabolic process                     | MYOM1                          | −2.5          |
|                                               | HP                             | −1.6          |
|                                               | CDK5R1                         | 0.8           |
|                                               | MEP1B                          | 1.3           |
Table 2 Identification of the major biological processes of the genes differentially expressed in hepatic tissue (Continued)

| Biological Processes | Gene Symbols | Fold Change |
|----------------------|-------------|-------------|
| multicellular organismal process | LOXL4, FUT5, HERC6, LOC515676, ISG15 | 1.6, 1.6, 1.8, 1.9, 2.5 |
| single-multicellular organism process | MYOM1, SFRP1, HP, MEP1B, LOX4 | −2.5, −1.8, −1.6, 1.3, 1.6 |
| reproduction | HP | −1.6 |
| response to stimulus | cellular defense response | LOC100126815, MGC126945, LOX4 | −2.4, −1.8, 1.6 |
| immune response | LOC100126815, MGC126945, HP, IGL1 | −2.4, −1.8, −1.6, 2.1 |
| response to external stimulus | HP, MEP1B | −1.6, 1.3 |
| response to stress | HP | −1.6 |
| Not found | C20H5orf49, LOC789904, SLC22A9, CFH, SLC26A10, SAA2, M-SAA3, LOC100847494, LOC100335975, LOC617654 | −1.9, −1.8, −1.7, 1.6, −1.8, −1.5, −1.4, −1.2, −0.9, 1.4, 4.2 |
| Unassigned | C4H7orf57, MT1E, MT1A, THRSP, KIAA1324, NGEF, GSTA5, ACMSD, NHEDC1, NEFH, G0S2, LOC524810, IF27, IF6 | −4.4, −3.4, −3.3, −1.7, −1.6, −1.4, −1.3, −1.2, −1.1, −1.1, −1.1, 1.9, 2.6, 3.3, 3.7 |

All genes modulated in the liver by the vitamins treatment, including those that were not found or classified by the Panther system are listed. The fold change observed by microarray analysis varies from −4.4 to 4.2 and only significantly (FDR ≤ 0.05) expressed genes (compared to control) are shown.

As shown in Tables 1 and 3, some of the genes identified by microarray in liver and mammary gland were annotated and clustered into three major gene ontology groups: Protein Class, Molecular Function and Biological Process. In Tables 2 and 4, gene expression clusters are categorized within biological processes (levels 1, 2 and 3). This allows looking for statistically over- and under-represented biological process categories among the genes. Most of the genes modulated in the liver by at least one of the vitamin supplements were associated to developmental process, protein metabolic process, transport and immune response (Table 2). However, protein metabolic process was over-represented (with 9 genes: MYOM1, HP, CDKSRI, MEP1B, LOXL4, FUT5, HERC6, LOC515676 and ISG15) in the gene list affected by treatments in the liver (Table 2). In the mammary gland, where very few genes were affected by the vitamin treatments, the over-represented biological process was developmental process involving 4 genes: CIDEA, POSTN, GPR110 and IRX6 (Table 4).

Gene symbols were uploaded to the Panther workspace in order to classify the genes of interest by selecting the Bos taurus reference gene list based on the selected
Fig. 2 (See legend on next page.)
organism [18]. Notwithstanding, some genes in both tissues (liver and mammary gland) could not be assigned to any biological process or molecular function category by Panther classification system (Tables 1, 2, 3 and 4). It is also possible that there is no experimental data to support their biological annotation.

Discussion

Microarray analysis was used to investigate the effects of vitamin B9 and B12 supplements given alone or in combination during the peripartum early lactation period on liver and mammary gland tissues. The expression of only a limited number of genes was modulated by the vitamin treatments in both tissues, which suggests a subtle vitamin effect on the tissue metabolism that would have been better characterized using a larger population. Notwithstanding, the qPCR analyses show that, in liver, expression of keys genes, such as DLK1, LOXL4, G0S2, GSTA5, HP, MT1A, IFI27 and SFRP1 was modulated at different extents (significant effects for five genes and a strong trend for three genes) by the vitamin treatments. Delta-like 1 homolog (DLK1/Pref-1) is a surface marker of hematopoietic progenitor cells (HPCs) associated with less differentiated hepatocellular phenotypes [19] and it has been shown to act in vitro as an inhibitor of Notch signaling [20, 21] to promote liver regeneration [21]. Interestingly, DLK1 is an imprinted gene which is involved in lipid metabolic reprogramming [22]. An increased concentration of this biomarker in blood serum is associated with hepatic cancer [23] whereas downregulation of DLK1 expression through an epigenetic mechanism contributes to attenuate liver disease [24]. Because vitamin B9 plays a major role in de novo formation of methyl groups and vitamin B12 is required for the remethylation cycle, we can speculate that DLK1 expression could also be repressed in the liver of the lactating cows through an epigenetic mechanism. Because DLK1 suppresses glucose production and fatty acid synthesis and oxidation in hepatocytes [25], supplementation of both vitamins B9 and B12 might increase liver metabolism through a genomic imprinting mechanism which negatively impacts the DLK1 pathway.

Lysyl oxidase-like member 4 (LOXLA4), a matrix-remodeling enzymes, is extracellularly secreted and significantly contributes to ECM deposition [26]. Activity of lysyl oxidase (LOX) and LOX like proteins are correlated to collagen and elastin deposition and, in adult mammals, are essential to tissue maintenance [27]. Recent studies have provided compelling evidence that G0S2 is abundantly expressed in metabolically active tissues such as liver, and acts as a molecular brake on triglyceride catabolism [28]. Triglyceride hydrolase activity of adipose triglyceride lipase can be selectively inhibited by G0S2 [28]. Hence, increasing the expression of G0S2 decreased lipolysis [29] which is supported by the reduction of plasma concentrations of non-esterified fatty acids in cows receiving vitamin B9 supplements, alone or combined with vitamin B12 in the present study. Although increased IFI27 expression was not significant, the pattern was highly similar to G0S2 thus suggesting a similar B9 supplement effect on the liver for this gene. Expression of the alpha-inducible protein 27 (IFI27) is up-regulated during inflammatory wound repair process [30] and expression of this gene also alters immune response and mitochondrial function [31]. Interestingly, DLK1 locus expression is also associated with a restriction of the mitochondrial metabolism [32]. These gene expression patterns support the hypothesis that both vitamins B9 and B12 improve the hepatic function which might reduce metabolic stress during the transition period and early lactation of dairy cows. This is further supported by the marked reduction of the HP and MT1A genes. The liver is the major site for the synthesis of acute phase proteins including haptoglobin (HP) and metallothionein 1A (MT1A) [30]. During stress response, it is reported that physiological processes aimed on redistribution of energy utilization in specific organs stimulating mobilization of body reserves. In mammary gland, administration of the three vitamin treatments had a very limited effect on gene expression as described above. Interestingly, in the present study, whereas vitamin treatments had no effect on milk total solids yield and dry matter intake, vitamin B9 supplements, given alone or in combination with vitamin B12, decreased body condition score losses during the first weeks of lactation as well as plasma concentrations of non-esterified fatty acids and β-hydroxybutyrate [9] suggesting an improvement in energy balance for these cows.

In the present study, all the genes that have their expression affected by the vitamin treatments in the liver, are involved in tissue repair, resorption of inflammation and lipid metabolism although no mode of action can be clearly identified. During the first weeks of lactation, dairy cows are generally in negative energy balance because nutrient intake increases less rapidly than nutrient demand for initiation of lactation which leads to mobilization of body reserves. Cows are losing
Fig. 3 (See legend on next page.)
body condition score and non-esterified fatty acids are released from adipose tissues and their plasma concentrations increased. During this period, dairy cows are also prone to liver steatosis because hepatic uptake of non-esterified fatty acids is greater than the amounts oxidized or secreted by the liver [33]. Accumulation of lipids in liver affects integrity and function of hepatic cells [33]; in response, liver parenchymal cells produce an acute-phase glycoprotein haptoglobin [34]. Because a decrease in DLK1 can improve fatty acid oxidation from hepatocytes [25], an improved β-oxidation of non-esterified fatty acids in liver could help to reduce ketone body formation and plasma concentrations of β-hydroxybutyrate. The improvement in energy balance observed in cows receiving supplementary vitamin B9, alone or combined with vitamin B12, likely reduced the liver burden caused by mobilization of body fat reserves which could explain the changes in hepatic gene expression described above. For instance, the increase of LOXL4 and G0S2 strongly support that these treatments protect body fat from catabolism. Prevention of liver damage or improved liver performance is not only important for maintaining liver function but also for general health of high-yielding dairy cows.

Conclusion
In the present study, a supplement of vitamin B9, given alone or in combination with vitamin B12, reduced mobilization of body fat reserves and hepatic lipid catabolism in early lactation. Changes in expression of genes described above support the hypothesis that hepatic tissue integrity in early lactation was improved by these vitamin supplements.

Methods
Animals and treatments
For the purpose of the present study, biopsies of hepatic and mammary tissues were taken from 24 multiparous Holstein cows from the dairy herd at the Agriculture and Agri-Food Canada Research Centre (Sherbrooke, Quebec, Canada) at the end of a larger study [9]. Care of cows followed the guidelines of the National Farm Animal Care Council (2009) [35]. Animals were kept in a tie-stall barn under 18:30 h of light per day (05:00 to 23:30 h) and milked twice daily (07:30 and 19:30 h). The experimental period began 3 weeks before the expected date of calving until parturition and, then a lactation diet both formulated to meet or exceed the National Research Council (NRC) recommendations [36]. Long hay (0.5 kg) was given at 07:30 h and total mixed ration was served once daily at 08:30 h. Cows had free access to water.

Cows were assigned to 6 blocks of 4 animals each according to their 305-d milk production during the previous lactation. Within each block, cows were randomly assigned to one of the following treatments: weekly intramuscular injections of 5 mL of either saline 0.9 % NaCl (Control group), 320 mg of folic acid (MP Biomedicals, Solon, OH, USA; (Vitamin B9 group), 10 mg of cyanocobalamin (5 000 μg/mL, Vetoquinol, Lavaltrie, Quebec, Canada; (Vitamin B12 group) or 320 mg of pteroylmonoglutamic acid and 10 mg of cyanocobalamin (B9 + B12 group). Thus, there were 6 animals per treatment group.

Biological material collection and tissue handling
Mammary gland and hepatic tissues were obtained from the lactating dairy cows, 64 ± 3 days after calving. Biopsies were performed under local anesthesia. The process of hepatic biopsies uses ultrasound guidance to minimize the hemorrhagic risks [4]. Both procedures were approved by the Institutional Committee on Animal Care of the Sherbrooke Research and Development Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada according to the guidelines of the Canadian Council on Animal Care [37]. Tissues were immediately frozen into liquid nitrogen and stored at −80 °C until use.

Total RNA isolation and purification
Total RNA was extracted from hepatic and mammary tissues by using a QIAzol Lysis Reagent (QIAGEN Inc., Toronto, ON, Canada) following the original manufacturer’s protocol, with slight modifications. Briefly, frozen samples (100 mg of tissue) were homogenized in 2 mL of QIAzol Lysis Reagent on ice using a Tissue-Tearor. A volume of 600 μL QIAzol Lysis Reagent was added to 400 μL of homogenate; the mixture was vigorously vortexed and kept at room temperature for 5 min to promote dissociation of nucleoprotein complexes. A volume of 200 μL of chloroform was added; the mixture was shaken and left at room temperature for 3 min followed by a centrifugation at 12 000 × g for 15 min at 4 °C to remove lipids. After centrifugation, the aqueous fraction (upper layer) was taken and RNA was precipitated by...
| Treatment Gene symbol | Gene name | Treatment regulation effect | Molecular Function | Biological Process | Protein Class |
|-----------------------|-----------|----------------------------|--------------------|-------------------|---------------|
| B9 POSTN              | Periostin  | Up-                        | receptor binding   | cell communication| signaling molecule |
|                       |           |                            |                    | cell-matrix adhesion| cell adhesion molecule |
|                       |           |                            |                    | visual perception  |               |
|                       |           |                            |                    | sensory perception |               |
|                       |           |                            |                    | mesoderm development|               |
|                       |           |                            |                    | skeletal system development| |
|                       |           |                            |                    | muscle organ development|               |
|                       |           |                            |                    | transferase activity, transferring glycosyl groups | protein glycosylation |
|                       |           |                            |                    | hydrolase activity | glycosyltransferase |
|                       |           |                            |                    | cation transmembrane transporter activity | |
|                       |           |                            |                    | proton-transporting ATP synthase activity, rotational mechanism | |
|                       |           |                            |                    | nucleobase-containing compound | |
|                       |           |                            |                    | metabolic process | | |
|                       |           |                            |                    | cation transport | |
|                       |           |                            |                    | ATP synthase | |
|                       |           |                            |                    | hydrolase | |
| LOC78576              | androgen binding protein beta-like | Down- | Unassigned | Unassigned | Unassigned |
| MGC126945             | uncharacterized protein MGC126945 | Down- | receptor activity | B cell mediated immunity | immunoglobulin receptor superfamily |
|                       |           |                            |                    | antigen processing and presentation | major histocompatibility complex antigen |
|                       |           |                            |                    | cellular defense response | |
| CIDEA                 | cell death-inducing DFFA-like effector a | Down- | Unassigned | induction of apoptosis | Unassigned |
| B12 GPR110            | G-Protein Coupled Receptor 110-Related | Up- | G-protein coupled receptor activity | spermatogenesis | G-protein coupled receptor |
|                       |           |                            |                    | immune response | antibacterial response protein |
|                       |           |                            |                    | synaptic transmission | |
|                       |           |                            |                    | neurotransmitter secretion | |
|                       |           |                            |                    | mesoderm development | |
|                       |           |                            |                    | heart development | |
|                       |           |                            |                    | response to stress | |
|                       |           |                            |                    | intracellular protein transport | |
|                       |           |                            |                    | synaptic vesicle exocytosis | |
|                       |           |                            |                    | sequence-specific DNA binding transcription factor activity | |
|                       |           |                            |                    | sequence-specific DNA binding transcription factor activity | |
|                       |           |                            |                    | transcription from RNA polymerase II promoter | |
|                       |           |                            |                    | ectoderm development | |
|                       |           |                            |                    | nervous system development | |
|                       |           |                            |                    | regulation of transcription from | |
|                       |           |                            |                    | RNA polymerase II promoter | |
| IRX6                  | iroquois homeobox 6 | Up- | sequence-specific DNA binding transcription factor activity | transcription from RNA polymerase II promoter | homeobox transcription factor |
|                       |           |                            |                    | sequence-specific DNA binding transcription factor activity | nucleic acid binding |
| RAB15                 | Ras-related protein Rab-15 | Up- | Unassigned | Unassigned | Unassigned |
| B9 + B12 | LOC509034 | feline leukemia virus subgroup C receptor-related protein 2-like | Down | transmembrane | transporter activity transport | Transporter |
|----------|-----------|---------------------------------------------------------------|------|---------------|-----------------------------|-------------|
|         | IDO1      | indoleamine 2,3-dioxygenase 1                                 | Down | Unassigned    | Unassigned                  | Unassigned  |
|         | SECTM1    | SECTM1 protein                                                | Down | Unassigned    | Unassigned                  | Unassigned  |

Differentially expressed genes in mammary tissue were assigned to gene ontology pathways using the Panther tool. Some genes were not found in Panther genes list. Furthermore, among the genes ID found by the PANTHER system, some were not classified to a category. Only 3 genes ontology categories are presented: Molecular Function, Biological Process and Protein Class.

*Classification with the Panther gene list classification system of the genes differentially expressed in mammary tissue following supplementation with vitamin B9 (B9), vitamin B12 (B12) or both (B9 + B12) as compared to no vitamin treatment (Control)*
adding an equal volume of 70% ethanol. RNA was purified according to manufacturer’s procedure using RNeasy Mini Kit (QIAGEN Inc., Toronto, ON, Canada), including on-column DNase digestion. The purity, concentration, and integrity of total RNA intended for qPCR were assessed. Purity of the RNA was evaluated by absorbance (A) readings (ratio of A260/A230 and A260/A280) using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, US). NanoDrop ND-1000 spectrophotometer was also used to measure the concentration. All RNA samples passed the quality control. The RNA Integrity Number calculated by the Bioanalyzer software at McGill University and Génome Québec Innovation Center (Montreal, Quebec, Canada) ranged from 7.3 to 8.7.

**Microarray**
McGill University and Génome Québec Innovation Center (Montreal, Quebec, Canada) performed the microarray analysis. Cyanine 3-labeled CTP complementary RNA (cRNA) was produced with 50 ng of total RNA using

---

**Table 4** Identification of the major biological processes of the genes differentially expressed in mammary gland tissue

| Biological process                        | Genes | Symbol | Fold change |
|-------------------------------------------|-------|--------|-------------|
| apoptotic process                         |       |        |             |
| induction of apoptosis                     |       | CIDEA  | −1.9        |
| biological adhesion                       |       | POSTN  | 1.1         |
| cell adhesion                             |       |        |             |
| biological regulation                     |       | IRX6   | 1.7         |
| regulation of biological process          |       |        |             |
| cellular process                          |       | POSTN  | 1.1         |
| cell communication                        |       | GPR110 | 1.3         |
| death                                     |       | CIDEA  | −1.9        |
| ectoderm development                      |       | IRX6   | 1.7         |
| mesoderm development                      |       | POSTN  | 1.1         |
| system development                        |       | GPR110 | 1.3         |
| immune system process                     |       |        |             |
| antigen processing and presentation       |       | MGC126945 | −1.5      |
| immune response                           |       | MGC126945 | −1.9      |
| localization                              |       |        |             |
| transport                                 |       | ATP6V1G3 | −0.9      |
| LOC509034                                 |       | GPR110 | 1.3         |
| metabolic process                         |       |        |             |
| nucleobase-containing compound            |       | ATP6V1G3 | −0.9      |
| metabolic process                         |       | IRX6   | 1.7         |
| protein metabolic process                 |       | FUT5   | 3.6         |
| multicellular organismal process          |       | POSTN  | 1.1         |
| single-multicellular organism process     |       | GPR110 | 1.3         |
| reproduction                              |       |        |             |
| gamete generation                         |       | GPR110 | 1.3         |
| response to stimulus                      |       |        |             |
| cellular defense response                  |       | MGC126945 | −1.9      |
| immune response                           |       | MGC126945 | −1.9      |
| response to stress                        |       | GPR110 | 1.3         |
| Not found                                 |       | LOC57510 | −1.3      |
| LOC57510                                  |       | VAV1   | −1.2         |
| LOC5614268                                |       | SAA2   | −0.9         |
| LOC5614268                                |       | C10H10orf53 | 1.4      |
| LOC751574                                 |       | H1FNT  | 4.9         |
| not found                                 |       | LOC785756 | −2.1      |
| LOC785756                                 |       | IDO1   | −1.2         |
| LOC785756                                 |       | SECTM1 | −0.9         |
| LOC785756                                 |       | RAB15  | 2.0         |

All genes modulated in the mammary tissue by the vitamins treatment, including those that were not found or classified by the Panther system are listed. The Fold Change, as using FlexArray microarray analysis, varies from −1.9 to 4.9 and only significantly (FDR ≤ 0.05) expressed genes (compared to control) are shown. Identification of the major biological processes of the genes differentially expressed in mammary tissue following supplementation with vitamin B9 (B9), vitamin B12 (B12) or both vitamins (B9 + B12) as compared to no vitamin treatment (Control)
the Low Input Quick Amp Labeling Kit, according to manufacturer’s instructions (Agilent Technologies, Inc). The quality of cRNA was evaluated by capillary electrophoresis on 2100 Electrophoresis Bioanalyzer instrument (Agilent technologies, Santa Clara, CA, USA). A total of 15 525 genes were analyzed via expression levels of 42 789 probes using the Agilent Bovine Genome Oligo Microarrays 4 × 44 K (G2519F-023647) (Agilent technologies, Santa Clara, CA, USA). Labeling, hybridization, and raw data extraction were performed by McGill University and Génome Québec Innovation Center (Montreal, Quebec, Canada) according to the manufacturer’s instructions, as previously described [38]. Hybridizations were performed by batch with samples randomly distributed. The hybridizations of microarrays were compared through a correlation matrix that enables the quick identification of poor and divergent replication (data not shown). Once the slides are scanned, the respective “tif” image was examined using the Agilent Feature Extraction (FE) software. Scan image information is displayed in the Scan Image Properties for images that were generated using the Agilent Scanner. Then data are extracted with the FE software. A quality control (QC) report is generated for each sample. The FE version 10.7.3.1 with GE1_107_Sep09 protocol and grid associated with the selected type of chip 023647_D_F_20110614 were used. All microarray datasets passed all the quality criteria and were then downloaded into the FlexArray microarray analysis software (http://gqinnovationcenter.com/documents/technicalNotes/technicalNotes_GQ06.pdf). Array data have been submitted to the public databases and assigned Gene Expression Omnibus (GEO) accession number is GSE77421. FlexArray, a Bioconductor R based software, was developed by Génome Québec to provide researchers with a user-friendly interface for the analysis of microarray experiments. Raw microarray expression intensities were corrected for background using normexp, according to Ritchie et al. [39]. Between-array normalization was performed so that the background corrected intensities have similar distributions across the arrays. Comparison of the vitamin treatments with the control tissue was performed by Cyber-T, a version of the t-test that uses a Bayesian estimate of the within treatment variance [40, 41]. Up- or downregulated genes lists were analyzed on Protein ANalysis THrough Evolutionary Relationships (Panther) classification system [42].

Quantitative real time-PCR

Quantifications by real-time PCR (qPCR) following reverse transcription were performed as previously described [43] with minor modifications. The reverse transcription PCR reactions were performed with the SuperScript II reverse transcriptase (Life Technologies Inc., Burlington ON, Canada) according to the manufacturer’s protocol and using 500 ng of total RNA extracted from each of the 24 animals. An equivalent quantity of cDNA is synthesized in a final reaction volume of 20 μL, giving a concentration of 25 ng/μl of cDNA. A pool of cDNA intended to estimate the efficiencies primers, was made using the cDNA of each animal. Primers were designed for each gene using the Primer Express 3 software package (Applied Biosysmets, Life Technologies Corporation, Burlington, ON, Canada) using the reference sequence from the RefSeq database of the National Center for Biotechnology Information depository. Primers for a total of 34 genes for both tissues were designed. Optimizations of primers were performed for each gene by testing different concentrations of both forward and reverse primers, each ranging from 50 to 900 nM. Estimations of primer efficiencies were analyzed using the standard curves made from a serial of seven dilutions (1/7.5, 1/15, 1/30, 1/60, 1/120, 1/240, 1/480) of the pool of the cDNA samples (25 ng/μl of cDNA). As 3 μl of each dilution were used in a final reaction volume of 10 μl for qPCR, the concentrations used per dilution were: 1, 0.5, 0.25, 0.125, 0.0625, 0.03125 and 0.015625 (ng/μl). Additional file 1 provides experimental information and PCR amplification efficiency for all genes. The qPCR reactions (10 μL, final volume) were performed on 96 well plates using Fast SYBR Green PCR Master Mix (Applied Biosystems) in a 7500 Fast Real Time-PCR System (Life Technologies, Burlington, ON, Canada) as the manufacturer’s instructions. The PCR thermal cycling conditions comprised an initial 20 s denaturation step at 95 °C followed by 40 cycles at 95 °C for 3 s followed by an annealing/elongation period at 60 °C for 30 s. A dissociation step was included for all amplifications to confirm the presence of single discrete PCR products of the expected size. Twenty-five genes (14 from hepatic tissue data and 11 from mammary gland tissue data) were subject to qPCR validation because they were found differentially expressed by microarray as expressed by log2 of their fold change. In addition, in the mammary gland, four genes (FOLR1, ELFS, B4GALT1 and LALBA) were chosen because of their implication in the metabolic pathway involving vitamins B9 and B12. The expression of 5 putative reference genes, namely actin beta (ACTB), ubiquitously-expressed transcript (LIXT), peptidylprolyl isomerase A (PPIA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), tyrosine 3-mono oxygenase/tryptophan 5-monoxygenase activation protein, zeta polypeptide (YWHAZ) was determined for all samples as recommended [44–46]. All the 24 animals were used to perform the qPCR analysis of 34 genes for both tissues. Once the more stable genes were selected, the normalization factor was calculated using a geometrical average as recommended [45]. The combination of ACTB and PPIA was appropriate to normalize...
the data from hepatic tissue. The appropriated combination was UXT and PPIA to normalize the data from mammary gland.

Data analysis and statistics
Using FlexArray microarray analysis, a significant result at a $P$ value $<0.05$ after false discovery rate correction with a minimum of ± two-fold change in gene expression for the respective treatment group compared to control tissues was considered biologically interesting. Gene category over-representation analysis consists in grouping genes into categories by some common biological property and then tested to find categories that are over represented amongst the differentially expressed genes. Gene ontology describes and categorizes gene products in three non-overlapping domains of molecular biology [47]. Panther (http://pantherdb.org) is a visualisation browser of GO [48], using version 10 which included other organisms. Panther ranks proteins (and their genes) according to Family (and subfamily), Molecular function, Biological process and Pathway. The process of classification is extensively explained by Mi and colleagues [42]. Only significant differentially expressed genes were analysed by qPCR. Data from qPCR were analyzed using SAS Institute procedures (2008). Means were assumed to be different at $P \leq 0.05$ and tended to differ at $0.05 < P \geq 0.1$. Normfinder indicated the interested combination of reference genes to normalize qPCR data.

Additional file

Additional file 1: Oligonucleotide primer sequences for quantitative PCR. (DOCX 32 kb)

Abbreviations
ECM, extracellular matrix components; GO, gene ontology; HPCs, hepatic progenitor cells; Panther, protein analysis through evolutionary relationships; qPCR, quantitative polymerase chain reaction.

Acknowledgements
The authors would like to thank Véronique Roy for her assistance with tissue sampling, Catherine Thibault for coordinating the extraction step and the design of the qPCR assay, Gloria-Gabrielle Ortega-Delgado providing technical assistance for performing qPCR assays and Steve Méthot for statistical analysis.

Funding
The present project was publicly supported research within Agriculture and Agroalimentaire Canada (ACC) using hepatic and mammary tissue samples collected during a project funded by Novacait - Agriculture et Agroalimentaire Canada - Fonds de recherche du Québec Nature et Technologies - Ministère de l’Agriculture, des Pêcheries et de l’Alimentation du Québec, Québec, Québec, Canada.

Availability of data and materials
All microarray datasets were then downloaded into the FlexArray microarray analysis software (http://ggm.innovationcenter.com/documents/technicalNotes/technicalNotes_G006.pdf). Array raw data have been submitted to the public databases. The following link (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77421) provides access to all data. The assigned Gene Expression Omnibus (GEO) accession number is GSE77421.

Authors’ contributions
BO, NB, MD and CLG contributed in the design of the study, interpretation of the results, writing of the manuscript, revision of its content and approval of the final version submitted for publication; MD realized the animal phase of the project; BO realized laboratory analyses; N. B. performed microarray analysis and supervised RT-PCR analyses; CLG was the principal investigator of the project. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Care of cows followed the guidelines of the National Farm Animal Care Council. The protocol was approved by the Institutional Committee on Animal Care of the Sherbrooke Research and Development Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC, Canada according to the guidelines of the Canadian Council on Animal Care. Consent to participate is not applicable because the study did not involve human subjects, human material or human data.

Author details
1Sherbrooke Research and Development Centre, Agriculture and Agri-Food Canada, Sherbrooke, QC J1M 0C8, Canada. *Current address: Valacta, Ste-Arines-de-Bellevue, Quebec H9X 3R4, Canada.

Received: 20 January 2016 Accepted: 30 June 2016
Published online: 15 August 2016

References
1. Lardinois CC, Mills RC, Eyhejhem CA, Hart EB. Rumen synthesis of the vitamin B complex as influenced by ration composition. J Dairy Sci. 1942;27(7):759–83.
2. Girard CL, Matte JJ. Effects of intramuscular injections of vitamin B12 on lactation performance of dairy cows fed dietary supplements of folic acid and rumin-protected methionine. J Dairy Sci. 2005;88(2):671–6.
3. Preynat A, Lapierre H, Thivierge MC, Palin MF, Matte JJ, Desrochers A, et al. Effects of supplements of folic acid, vitamin B12, and rumin-protected methionine on whole body metabolism of methionine and glucose in lactating dairy cows. J Dairy Sci. 2009;92(2):677–89.
4. Graulet B, Matte JJ, Desrochers A, Doepel L, Palin MF, Girard CL. Effects of dietary supplements of folic acid and vitamin B12 on metabolism of dairy cows in early lactation. J Dairy Sci. 2007;90(7):3442–55.
5. Scott JM. Folate and vitamin B12. Proc Nutr Soc. 1999;58(2):441–8.
6. Girard CL, Matte JJ, Tremblay GF. Gestion et lactation de laitière. Université Laval 2014. PhD Thesis. Univ. Laval, Quebec, QC, Canada, p. 301.
7. McEwen M, Reynolds K. Noninvasive detection of bilirubin using pulsatile absorption. Australas Phys Eng Sci Med. 2006;29(1):78–83.
8. Racette B, Matte JJ, Tremblay GF, Lapierre H. Effects of dietary supplements of folic acid and vitamin B12 on performance of dairy cows: a field trial. J Dairy Sci. 2009;92(2):677–89.
9. Menzies K, Kefefee C, Macmillan KL, Nicholas KR. Insulin regulates milk protein synthesis at multiple levels in the bovine mammary gland. Funct Integr Genomics. 2009;9(2):197–217.
10. Duplessis M. Impact d’un supplément combiné d’acide folique et de vitamine B12 en période prépartum et en début de lactation chez la vache laitière. Université Laval 2014. PhD Thesis. Univ. Laval, Quebec, QC, Canada, p. 301.
11. Larsen M, Kristensen NB. Precursors for liver gluconeogenesis in periparturient dairy cows. Animal. 2013;7(10):1640–50.
12. Amasal DM, Veenhuizen JJ, Drackley JK, Cooley MH, McGilliard AD, Young JW. Metabolism of propionate, glucose, and carbon dioxide as affected by exogenous glucose in dairy cows at energy equilibrium. J Dairy Sci. 1990;73(5):1244–54.
13. Danfaer A, Tetens V, Agergaard N. Review and an experimental study on the physiological and quantitative aspects of gluconeogenesis in lactating ruminants. Comp Biochem Physiol B Biochem Mol Biol. 1995;111(2):201–10.
14. Nafkov RA, Betz DC. Carbohydrate and lipid metabolism in farm animals. J Nutr. 2007;137(3):702–5.
15. Grummer RR. Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. J Anim Sci. 1995;73(9):2820–33.
16. McCarthy SD, Waters SM, Kenny DA, Diskin MG, Fitzpatrick R, Patton J, et al. Negative energy balance and hepatic gene expression patterns in high-yielding dairy cows during the early postpartum period: a global approach. Physiol Genomics. 2010;42A(3):189–99.

17. Connor EE, Sifred S, Elaesser TH, Evock-Clover CM, Van Tassell CP, Sonstegard TS, et al. Effects of increased milking frequency on gene expression in the bovine mammary gland. BMC Genomics. 2008;9:362.

18. Mi H, Murugananujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013;8(8):1551–66.

19. Jelher P, Santoni-Rugiu E, Rasmussen M, Fris SL, Nielsen JH, Tygstrup N, et al. Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell-mediated liver regeneration. Hepatology. 2007;45(6):1462–70.

20. Falix FA, Aronson DC, Lamers WH, Gaemers IC. Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta. 2012;1822(6):988–95.

21. Zhu NL, Asahina K, Wang J, Ueno A, Lazaro R, Miyaoka Y, et al. Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem. 2012;287(13):10355–67.

22. Tsukamoto H, Metabolic reprogramming and cell fate regulation in alcoholic liver disease. Pancreatology. 2015;15(4 Suppl):65–1.

23. Li H, Cui ML, Chen TY, Xie HY, Cui Y, Tu H, et al. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma. Turnour Biol. 2015;36(11):8399–404.

24. Pan RL, Xiang LX, Wang P, Liu XY, Nie L, Huang W, et al. Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like-1. Hepatology. 2015;61(5):1708–20.

25. Lee YH, Yun MR, Kim HM, Jeon BH, Park BC, Lee BW, et al. Exogenous administration of DLK1 ameliorates hepatic steatosis and regulates gluconeogenesis via activation of AMPK. Int J Obes (Lond). 2016;40(2):356–65.

26. Busnadiego O, Gonzalez-Santamaria J, Lagos H, Guena-Viniegra J, Pichol-Thievend C, Muller L, et al. LOXL4 is induced by transforming growth factor beta1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. Mol Cell Biol. 2013;33(12):2388–401.

27. Hayashi K, Song KS, Mercier F, Boyd CD, Csiszar K, Hayashi M. Comparative immunocytochemical localization of lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL) proteins: changes in the expression of LOXL during development and growth of mouse tissues. J Mol Histol. 2004;35(8):845–55.

28. Yang X, Zhang X, Heckmann BL, Lu X, Liu J. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-alpha (TNF-alpha)-induced lipolysis in adipocytes. J Biol Chem. 2010;285(47):40477–85.

29. Yang X, Lu X, Lombe M, Rha GB, Chi YI, Guerin TM, et al. The G0I(G1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 2011;13(3):194–205.

30. Gessner DK, Schlegel G, Keller J, Schwarz FJ, Ringseis R, Eder K. Expression of target genes of nuclear factor E2-related factor 2 in the liver of dairy cows in the transition period and at different stages of lactation. J Dairy Sci. 2013;96(2):1038–43.

31. Hisao CP, Araneta M, Wang XM, Saligan LN. The association of IFI27 expression and fatigue intensification during localized radiation therapy: implication of a para-inflammatory bystander response. Int J Radiat Oncol Biol Phys. 2013;86(3):480–9.

32. Qian P, He XC, Paulson A, Li Z, Tao F, Perry JM, et al. The Dlk1-Gtl2 Locus during localized radiation therapy: a comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007;23(20):2700–7.

33. Baldis P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001;17(6):509–19.

34. Katoh N. Relevance of apolipoproteins in the development of fatty liver and fatty liver-related peripartum diseases in dairy cows. J Vet Med Sci. 2007;69(7):959–64.